Passage BIO, Inc S-4/A, filed Sep 21, 2026

Passage BIO, Inc. (PASG)

Passage Bio and Remix Therapeutics plan a two-step merger, rename the combined company Remix Therapeutics, and launch a concurrent financing expected to generate approximately $100.0 million; Remix stockholders are expected to own approximately 65% of the combined company. AI summary